Live Analyst Rating Changes 4859 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrew Paine
CLSA
Andrew Paine
CLSA
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-22.1%
Average Return
0 of 1 calls profitable · -27.0% vs benchmark
📈 Across the calls we could measure, roughly 0% of Andrew Paine's ratings turned a profit when each position was held for 1 year — averaging -22.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

5 Buy 1 Hold 0 Sell
Andrew's Stock Coverage 12 ratings · 2026-07-02
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
AU:CSL
CSL
 Oct 13, 2025 BUY Strong Buy
+56.0% avg upside
15 analysts
$275.00
132.24% Upside
 ·
AU:TLX
Telix Pharmaceuticals
 Oct 03, 2025 BUY Strong Buy
+48.4% avg upside
13 analysts
$24.25
42.55% Upside
 ·
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
 Sep 02, 2025 BUY Strong Buy
+44.9% avg upside
11 analysts
$47.25
66.26% Upside
 ·
AU:COH
Cochlear
Mar 17, 2025 BUY Hold
+48.4% avg upside
15 analysts
$290.00
144.73% Upside
 ·
AU:PME
Pro Medicus Limited
 Feb 14, 2025 BUY Strong Buy
+29.8% avg upside
8 analysts
$308.00
51.92% Upside
 ·
AU:SHL
Sonic Healthcare Limited
 Jan 28, 2025 BUY Buy
+23.0% avg upside
12 analysts
$31.10
48.26% Upside
 ·
AU:ANN
Ansell
 Jan 28, 2025 BUY Buy
+5.0% avg upside
9 analysts
$38.00
18.30% Upside
 ·
AU:RHC
Ramsay Health Care
 Jan 28, 2025 HOLD Hold
-8.0% avg upside
14 analysts
$35.75
17.84% Downside
 ·
AU:IDX
Integral Diagnostics Ltd.
 Sep 30, 2024 BUY Buy
+56.5% avg upside
12 analysts
$3.30
64.25% Upside
 ·
AU:IMM
Immutep Ltd
 Oct 07, 2022 BUY Buy
+1033.1% avg upside
4 analysts
$1.25
2093.06% Upside
 ·
AU:PNV
Polynovo
Oct 07, 2022 BUY Strong Buy
+94.9% avg upside
5 analysts
$1.90
103.22% Upside
 ·
RMD
Resmed
 Aug 15, 2022 BUY Buy
+18.4% avg upside
27 analysts
 — -22.1%
🔒 7 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrew Paine — Frequently Asked Questions
How accurate are Andrew Paine's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Andrew's ratings were profitable over a one-year hold, with an average return of -22.1% per rating, or -27.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Andrew ranked on 13Foresight?
Andrew Paine is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrew cover?
Andrew most recently has ratings on AU:CSL, AU:TLX, AU:RMD, AU:COH, AU:PME, AU:SHL, AU:ANN, AU:RHC, AU:IDX, AU:IMM, AU:PNV, RMD. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.